Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on TAIHUA PLC. We currently have 2 research reports from 1 professional analysts.
|09Mar17 16:13||RNS||Holding(s) in Company|
|07Mar17 14:01||RNS||Cancellation of Tender Offer Shares|
|22Feb17 14:00||RNS||Result of Tender Offer and Directors' Interests|
|22Feb17 07:00||RNS||Result of Tender Offer and Directors' Interests|
|06Feb17 15:41||RNS||Proposed Tender Offer|
|30Jan17 13:39||RNS||Trading Update re Forsythia|
|18Jan17 15:14||RNS||AIM Rule 26 Website update|
Frequency of research reports
Research reports on
Life Sciences Review - London calling to the faraway biotech: Now a bubble is declared and IPOs hail down
08 Jun 15
The British economy has 'cranked up several gears', according to the Confederation of British Industry (CBI), after a hiatus in the first quarter. Experts have passed off the slowdown in the first quarter of 2015 as a minor bump in the road for growth within the economy. The Office for National Statistics (ONS) in April 2015 revealed the UK economy had turned in the slowest quarterly growth for two years at 0.3 percent, driven by a widening trade deficit according to economists, which strengthened fears that the economy could well be heading for a slowdown. However, research conducted by the CBI put forward that business activity stepped up markedly in the three months to May, particularly led by strong growth in the professional services sector. Moreover, The Organisation for Economic Co-operation and Development (OECD) said that in spite of weakness in UK GDP in Q1 2015, growth has carried on at a "healthy pace", boosted by reasonable rises in consumption, employment and in real wages.
US pharma deals but don’t forget the rest!
09 Mar 15
While Abbvie and Pharmacyclics work out their $21bn nuptial party arrangements, there has also been some positive news over here on the UK biotech scene. British biotech company Heptares, has been bought by Japan’s Sosei in a deal worth around £250m. Which if you had not just read the $21bn number would seem like a result. This for just two COPD products, but then it has been ‘just’ hard slog since the 1990s to get to this place. Astra Zeneca signed a three year deal with Orca Pharmaceuticals for its Auto-immune program to the tune of $122m which has taken considerably less time, and overall there are definitely signs of life across the sector. So much so that Messrs Woodford and Mellon have also announced plans to invest in a significant way.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
Interim results lead to upgrades
27 Mar 17
Bioventix reported a strong set of interim results with revenues increasing by 32% (c.12-17% at constant exchange rates (CER)), driven largely by the continued roll-out of its customers’ Vitamin D assay products. This, in turn, led to a 41% increase in pre-tax profits and a 40% increase in adjusted EPS; which is reflective of the operational gearing of the business. We are upgrading our adjusted EPS to 78.7p (+5%) and, consequently, are raising our target price to 1750p. At this price level, the shares would trade on a 22.4x FY 2018 P/E and an EV/EBITDA of 17x. We await confirmation of Siemen’s high sensitivity troponin assay launch, expected in FY 2018.
27 Mar 17
Elecosoft* (ELCO): Steadily building profits (CORP) | Bioventix* (BVXP): Interim results lead to upgrades (CORP) | Hurricane Energy (HUR): Halifax discovery (BUY) | KBT Business Technology* (KBT): interims and contract win (CORP) | Independent Oil & Gas* (IOG): Licence updates (CORP)
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Sinclair Pharma - Aesthetically Positioned to Continue Double-Digit Growth
23 Mar 17
With an innovative and differentiated product portfolio of injectable devices addressing the fast-growing aesthetics market, Sinclair is best positioned to continue to achieve double-digit revenue growth in the medium term.
N+1 Singer - Futura Medical - Licensing deal for CSD500 in Portugal
22 Mar 17
The agreement with F Lima further extends the market reach of CSD500, Futura’s erectogenic condom, and brings the total number of distribution partners to eight. The deal is in line with the company’s stated strategy of partnering with leading regional players in the consumer products space. We expect the condom to be launched in Portugal later this year. We retain a positive stance.